Prognostic analysis of hidradenocarcinoma: a SEER-based observational study

Figures & data

Table 1. The distribution of the main clinicopathological characteristics of hidradenocarcinoma patients.

Variables	Number of patients	Primary site
		Head and neck	Trunk and limbs	χ^2	P value
Sex				2.733	.098
Male	170 (58.8%)	78 (64.5%)	92 (54.8%)
Female	119 (41.2%)	43 (35.5%)	76 (45.2%)
Age				2.083	.353
0–29 years	12 (4.2%)	5 (4.1%)	7 (4.2%)
30–59 years	102 (35.3%)	37 (30.6%)	102 (35.3%)
≥60 years	175 (60.6%)	79 (65.3%)	175 (60.6%)
Race				0.146	.702
White	231 (79.9%)	98 (81.0%)	133 (79.2%)
Others	58 (20.1%)	23 (19.0%)	35 (20.8%)
Tumour size				5.857	.439
1–10 mm	47 (16.3%)	25 (20.7%)	22 (13.1%)
11–20 mm	36 (12.5%)	17 (14.0%)	19 (11.3%)
21–30 mm	24 (8.3%)	9 (7.4%)	15 (8.9%)
31–40 mm	23 (8.0%)	7 (5.8%)	16 (9.5%)
41–50 mm	15 (5.2%)	5 (4.1%)	10 (6.0%)
>50 mm	17 (5.9%)	5 (4.1%)	12 (7.1%)
Unknown	127 (43.9%)	53 (43.8%)	74 (44.0%)
Grade				0.361	.835
I–II	61 (21.1%)	27 (22.3%)	34 (20.2%)
III–IV	22 (7.6%)	10 (8.3%)	12 (7.1%)
Unknown	206 (71.3%)	84 (69.4%)	122 (72.6%)
AJCC stage				0.655	.721
I–II	124 (42.9%)	54 (44.6%)	70 (41.7%)
III–IV	19 (6.6%)	9(7.4%)	10(6.4%)
Unknown	146 (50.5%)	58 (47.9%)	88 (52.4%)
T stage				4.879	.087
T1–2	131 (45.3%)	52 (43.0%)	79 (47.0%)
T3–4	18 (6.2%)	12 (9.9%)	6 (3.6%)
Unknown	140 (48.4%)	57 (47.1%)	83 (49.4%)
N stage				0.918	.632
N0	225 (77.9%)	97 (80.2%)	128 (76.2%)
N1–2	10 (3.5%)	3 (2.5%)	7 (4.2%)
Unknown	54 (18.7%)	21 (17.4%)	33 (19.6%)
M stage				0.190	.909
M0	242 (83.7%)	102 (84.3%)	140 (83.3%)
M1	6 (2.1%)	2 (1.7%)	4 (2.4%)
Unknown	41 (14.2%)	17 (14.0%)	24 (14.3%)
Primary site surgery				0.842	.359
Performed	261 (90.3%)	107 (88.4%)	154 (91.7%)
Unperformed	28 (9.7%)	14 (11.6%)	14 (8.3%)

AJCC: American Joint Committee on Cancer; T: Tumour; N: Node; M: Metastasis.

Figure 1. (A) Overall survival (OS) and cancer-specific survival (CSS) of hidradenocarcinoma patients. (B) Overall survival (OS) and cancer-specific survival (CSS) of hidradenocarcinoma patients stratified by primary site.

Table 2. Survival rates of hidradenocarcinoma patients stratified by primary site.

Variables	All patients	Primary site
		Head and neck	Trunk and limbs	P value
Overall survival				.191
1-year OS rate (95%CI)	92.8% (89.7%–95.9%)	91.3% (86.2%–96.4%)	93.8% (90.1%–97.5%)
3-year OS rate (95%CI)	84.5% (79%–90%)	83.4% (76.3%–90.5%)	85.2% (79.5%–90.9%)
5-year OS rate (95%CI)	75.9% (70.4%–81.4%)	72.6% (63.6%–81.6%)	78.1% (71.2%–85%)
10-year OS rate (95%CI)	60.2% (52.6%–67.8%)	54.1% (41.9%–66.3%)	64.5% (54.9%–74.1%)
Mean OS (months)	122.8	117	125
Median OS (months)	164	–	164
Cancer-specific survival	–	–	–	.559
1-year CSS rate (95%CI)	98.2% (96.6%–99.8%)	97.3% (94.4%–100%)	98.7% (96.9%–100%)
3-year CSS rate (95%CI)	97.2% (95.0%–99.4%)	96.1% (92.2%–100%)	97.9% (95.5%–100%)
5-year CSS rate (95%CI)	93.8% (90.5%–97.1%)	93.1% (87.6%–98.6%)	94.4% (90.3%–98.5%)
10-year CSS rate (95%CI)	90.5% (85%–96%)	89.2% (80%–98.4%)	91.7% (85.2%–98.2%)
Mean CSS (months)	165.9	163.9	162.7
Median CSS (months)	–	–	–

OS: overall survival; CSS: cancer-specific survival; CI: confidence interval.

Figure 2. Overall survival (OS) of hidradenocarcinoma patients stratified by sex, race, histologic grade, American Joint Committee on Cancer (AJCC) stage, and primary site surgery.

Figure 3. Cancer-specific survival (CSS) of hidradenocarcinoma patients stratified by sex, race, histologic grade, American Joint Committee on Cancer (AJCC) stage, and primary site surgery.

Figure 4. Overall survival (OS) and cancer-specific survival (CSS) of hidradenocarcinoma patients stratified by tumour size and age.

Table 3. Univariable survival analysis of hidradenocarcinoma patients.

Variables	Overall survival		Cancer-specific survival
	HR (95%CI)	P value	HR (95%CI)	P value
Primary site
Head and neck	Reference		Reference
Trunk and limbs	0.768 (0.499–1.182)	0.231	0.739 (0.267–2.044)	.561
Gender
Male	Reference		Reference
Female	0.981 (0.629–1.529)	0.933	0.831 (0.283–2.436)	.736
Age
0–29 years	Reference		Reference
30–59 years	–	0.909	–	.936
≥60 years	–	0.893	–	.931
Race
White	Reference		Reference
Others	0.892 (0.502–1.584)	0.697	0.218 (0.758–6.495)	.146
Tumour size
1–10 mm	Reference		Reference
11–20 mm	1.62 (0.603–4.354)	0.339	–	.934
21–30 mm	2.617 (0.949–7.221)	0.063	–	.93
31–40 mm	1.876 (0.657–5.36)	0.24	–	.932
41–50 mm	3.282 (1.102–9.774)	0.033	–	.922
>50 mm	6.297 (2.434–16.289)	<0.001	–	.916
Unknown	2.027 (0.902–4.557)	0.087	–	.931
Grade
I–II	Reference		Reference
III–IV	0.811 (0.342–1.92)	0.633	0.472 (0.055–4.054)	.494
Unknown	0.771 (0.463–1.284)	0.771	0.489 (0.163–1.461)	.2
AJCC stage
I–II	Reference		Reference
III–IV	0.629 (0.224–1.768)	0.379	–	.984
Unknown	1.044 (0.671–1.623)	0.85	–	.976
T stage
T1–2	Reference		Reference
T3–4	1.975 (0.913–4.273)	0.084	1.244 (0.153–10.114)	.839
Unknown	1.192 (0.758–1.875)	0.447	0.976 (0.342–2.788)	.964
N stage
N0	Reference		Reference
N1–2	0.255 (0.035–1.836)	0.175	–	.981
Unknown	0.805 (0.436–1.485)	0.487	0.748 (0.168–3.325)	.703
M stage
M0	Reference		Reference
M1	0.417 (0.058–3.001)	0.385	–	.985
Unknown	0.683 (0.314–1.482)	0.335	1.133 (0.255–5.039)	.87
Surgery
Performed	Reference		Reference
Unperformed	0.738 (0.321–1.694)	0.473	–	.413

HR: hazard ratio; CI: confidence interval; AJCC: American Joint Committee on Cancer; T: Tumour; N: Node; M: Metastasis.

Table 4. Univariable survival analysis of hidradenocarcinoma patients stratified by primary site.

Variables	Head and neck				Trunk and limbs
	Overall survival		Cancer-specific survival		Overall survival		Cancer-specific survival
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Gender
Male	Reference		Reference		Reference		Reference
Female	0.837 (0.394–1.777)	0.643	3.501 (0.768–15.963)	0.106	1.164 (0.652–2.077)	0.608	0.181 (0.022–1.473)	.11
Age
0–29 years	Reference		Reference		Reference		Reference
30–59 years	–	0.921	–	0.961	–	0.931	–	.967
≥60 years	–	0.91	–	0.96	–	0.914	–	.964
Race
White	Reference		Reference		Reference		Reference
Others	1.124 (0.494–2.555)	0.78	1.962 (0.379–10.157)	0.422	0.736 (0.329–1.647)	0.455	2.527 (0.603–10.596)	.205
Tumour size
1–10 mm	Reference		Reference		Reference		Reference
11–20 mm	1.855 (0.566–6.08)	0.308	–	1	1.47 (0.244–8.837)	0.674	–	.937
21–30 mm	0.563 (0.066–4.824)	0.6	–	1	6.532 (1.355–31.474)	0.019	–	.934
31–40 mm	3.989 (1.068–14.902)	0.04	–	0.956	1.607 (0.267–9.666)	0.605	–	1
41–50 mm	4.78 (1.276–17.912)	0.02	–	0.953	2.744 (0.386–19.505)	0.313	–	1
>50 mm	5.768 (1.365–24.368)	0.017	–	0.953	10.404 (2.202–48.147)	0.003	–	.923
Unknown	1.756 (0.638–4.833)	0.276	–	0.96	2.927 (0.684–12.529)	0.148	–	.941
Grade
I–II	Reference		Reference		Reference		Reference
III–IV	1.252 (0.418–3.75)	0.688	0.736 (0.076–7.147)	0.791	0.451 (0.1–2.041)	0.301	–	.988
Unknown	0.707 (0.327–1.53)	0.379	0.263 (0.052–1.336)	0.107	0.815 (0.412–1.615)	0.558	0.805 (0.162–3.988)	.79
AJCC stage
I–II	Reference		Reference		Reference		Reference
III–IV	0.89 (0.26–3.038)	0.852	–	0.988	0.318 (0.042–2.382)	0.265	–	.989
Unknown	0.984 (0.505–1.917)	0.961	1.237 (0.273–5.601)	0.783	1.095 (0.604–1.982)	0.766	0.802 (0.2–3.209)	.755
T stage
T1–2	Reference		Reference		Reference		Reference
T3–4	1.443 (0.528–3.944)	0.475	1.591 (0.165–15.308)	0.688	2.888 (0.848–9.838)	0.09	–	.989
Unknown	0.966 (0.487–1.917)	0.921	0.912 (0.183–4.55)	0.911	1.356 (0.737–2.496)	0.327	0.992 (0.247–3.974)	.991
N stage
N0	Reference		Reference		Reference		Reference
N1–2	0.859 (0.117–6.312)	0.881	–	0.99	–	0.976	–	.991
Unknown	0.928 (0.386–2.23)	0.867	0.785 (0.094–6.572)	0.824	0.721 (0.305–1.705)	0.457	0.711 (0.087–5.803)	.75
M stage
M0	Reference		Reference		Reference		Reference
M1	–	0.976	–	0.991	0.742 (0.102–5.417)	0.769	–	.767
Unknown	0.997 (0.389–2.559)	0.996	2.542 (0.491–13.172)	0.266	0.383 (0.092–1.588)	0.186	–	.528
Surgery
Performed	Reference		Reference		Reference		Reference
Unperformed	0.528 (0.127–2.198)	0.38	–	0.57	0.939 (0.336–2.625)	0.904	–	.553

HR: hazard ratio; CI: confidence interval; AJCC: American Joint Committee on Cancer; T: Tumour; N: Node; M: Metastasis.

Data availability statement

The datasets generated during the present study are available in the official software. SEER* Stat version 8.3.9.1 repository (https://seer.cancer.gov/data/).